- Home
- Equipment
- north america
- vaccine targeting
Refine by
Vaccine Targeting Equipment Supplied In North America
13 equipment items found
Manufactured by:EnGen Bio LLC based inREDWOOD CITY, CALIFORNIA (USA)
While it has been believed that M1 is completely protected by the lipid membrane, we have discovered that a portion of it is in fact exposed and accessible to monoclonal antibody binding, and therefore represents a vaccine target. We have determined that it is critical to engineer the immunogen to allow the immune system to focus its response on the ...
Manufactured by:Vitruvian BioMedical, Inc. based inAddison, TEXAS (USA)
VITRUVIAN has obtained the Exclusive Global License for a Therapeutic Vaccine for the Prevention of Alzheimer's Disease. YM7555 - Alzheimer’s Disease Therapeutic Vaccine targeting ABeta and TAU. VITRUVIAN has received an Exclusive Global License for YM7555 which is a Therapeutic Vaccine technology for the prevention of ...
Manufactured by:Calder Biosciences, Inc. based inBrooklyn, NEW YORK (USA)
Targeted approach, focused responses. Substantially reduced risk vis-à-vis other modalities. Successful recombinant subunit vaccines elicit the highest. Ab responses; Shingrix vs. Zostavax, Gardasil, HBsAg (Recombivax, Engerix, Heplisav), HAV (Vaqta, ...
Manufactured by:Calder Biosciences, Inc. based inBrooklyn, NEW YORK (USA)
Calder’ protein engineering technology is based on targeted di-tyrosine (DT) crosslinking, which allows proteins to be locked in desired shapes. We apply this methodology to engineer novel vaccines that are locked in the shapes that elicit the most potently protective antibody ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
Auro Vaccines is developing a GeneVav prime/VesiculoVax™ boost therapeutic vaccine that targets all HCV genotypes for use as an adjunct to drug ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
Auro Vaccines has also developed a GeneVax prime/VesiculoVax boost therapeutic vaccine that targets all eight HBV genotypes for use as an adjunct to drug ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
ELI-008 is a multivalent lymph node–targeted AMP peptide vaccine developed to target p53 hotspot mutations. p53 is a tumor-suppressing protein that controls the cell cycle, DNA replication, and uncontrolled cell division during tumor growth.4 Mutations in the p53 protein lead to uncontrolled tumor progression and growth.4 ...
by:CuraVac Europe S.A. based inRixensart, BELGIUM
CuraVac is a clinical-stage biotechnology company developing the medical and commercial potential of a revolutionary technique for the production of specific Therapeutic Vaccines (or Active Targeted Immunotherapies) for autoimmune ...
by:BacVax, Inc. based inPhoenix, ARIZONA (USA)
Current commercial bacterial vaccines use toxin neutralization, capsule targeting, or multiple proteins. While these methods may work in some circumstances, many bacteria do not have toxin or capsule targets, and using several proteins in a vaccine is expensive and opens the opportunity for genetic escape by the bacteria. ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
ELI-007 is a multivalent lymph node–targeted AMP peptide vaccine developed to target BRAF gene mutations. The BRAF gene is part of an intracellular signaling pathway that drives cell growth and division.1 BRAF mutations can lead to uncontrolled cell growth and ultimately cancer. BRAF mutations are present in multiple types of ...
Manufactured by:Hygieia Biological Laboratories based inWoodland, CALIFORNIA (USA)
Preventative health including vaccination is a key focus of good animal management. Hygieia offers inactivated autogenous bacterins and vaccines which are custom manufactured from disease agents specifically found at an individual ranch, zoo, or other animal facility. This allows the producer or owner to tailor a vaccine formulation to ...
by:CuraVac Europe S.A. based inRixensart, BELGIUM
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
Vaccination is the most cost-effective tool for the control and prevention of infectious diseases. However, multiple inoculations are often required to achieve desirable protection even with potent antigens. In order to increase the therapeutic efficiency of such vaccines, adjuvants are used with vaccines to augment the immune response. ...